CHMP recommends BV+AVD for Hodgkin lymphoma

Print Friendly, PDF & Email


Brentuximab vedotin
Photo from Business Wire
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for brentuximab vedotin (BV). The CHMP has recommended approval for BV (Adcetris) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) to treat adults with previously untreated, CD30+, stage IV Hodgkin... [Read Article]
Print Friendly, PDF & Email

Combo bests standard care in younger CLL patients

Print Friendly, PDF & Email


2018 ASH Annual Meeting
©ASH/Scott Morgan 2018
In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger than 70 with untreated chronic lymphocytic leukemia (CLL). Patients who received IR had superior progression-free survival (PFS) and overall survival compared to patients who received fludarabine, cyclophosphamide, and rituximab... [Read Article]
Print Friendly, PDF & Email

Shorter R-CHOP regimen noninferior in certain DLBCL patients

Print Friendly, PDF & Email


Viola Poeschel, MD
© ASH/Scott Morgan 2018
A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy was noninferior in efficacy to the standard six cycles of R-CHOP in younger patients with favorable-risk diffuse large B-cell lymphoma (DLBCL), according to investigators of the FLYER trial. In addition,... [Read Article]
Print Friendly, PDF & Email

New PCNSL guidelines emphasize importance of patient fitness

Print Friendly, PDF & Email


Micrograph showing PCNSL
Image by Michael Bonert
New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis, aggressive treatment whenever possible, and multidisciplinary team support. A unique aspect for hematologic cancers, the guideline authors wrote, is that appropriate treatment requires input from neurology specialists. And they... [Read Article]
Print Friendly, PDF & Email

Biosimilar deemed equivalent to rituximab in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL). Overall response rates were similar—both exceeding 80%—in patients who received CT-P10 and those who received rituximab. In addition, adverse event (AE) profiles were comparable between the treatment arms.... [Read Article]
Print Friendly, PDF & Email

Bortezomib may overcome resistance in WM

Print Friendly, PDF & Email


Micrograph showing
Waldenström’s macroglobulinemia
Image from Michail Charakidis
and David Joseph Russell
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new study. Researchers assessed the impact of treatment with bortezomib and rituximab in patients with WM, based on their CXCR4 mutation status. The team... [Read Article]
Print Friendly, PDF & Email

Selinexor on fast track for DLBCL

Print Friendly, PDF & Email


Micrograph showing DLBCL
The U.S. Food and Drug Administration (FDA) has granted fast track designation to selinexor for the treatment of diffuse large B-cell lymphoma (DLBCL). The designation is for selinexor to treat DLBCL patients who have received at least two prior therapies and are not eligible for high-dose chemotherapy with stem cell rescue... [Read Article]
Print Friendly, PDF & Email